An alliance between Chr. Hansen and Jarrow Formulas now brings to US health food stores the only oral probiotic clinically documented to restore and maintain a healthy vaginal flora and reduce the risk of urogenital infections.

Milwaukee, WI – American women spend nearly 300 million dollars annually on non-prescription medications for the treatment of infections such as yeast and urinary tract infections. Experts estimate that three in four women at some point experience a urogenital infection.

To provide women a scientific and clinically documented natural solution, Chr. Hansen has signed an agreement with Jarrow Formulas, Los Angeles, California, USA, for the distribution of Urex-cap-5 to health food stores in the United States. Urex-cap-5 is a unique probiotic concept for women's health, and is the only oral probiotic concept clinically documented to restore and maintain a healthy vaginal flora and reduce the risk of urogenital infections. Jarrow will market the Urex concept under its brand name Fem-Dophilus™.     

The Urex concept is based on the world's most documented probiotic strains for women's health, Lactobacillus rhamnosus GR-1™ and Lactobacillus reuteri RC-14™. Licensed from Urex Biotech, Inc., it is produced and marketed globally by Chr. Hansen, the world leader in probiotics.

“The agreement with Jarrow Formulas is another very important step in our company's strategy to commercialize the Urex concept on a global scale and be the leading supplier of probiotic concepts for women's health,” said Steen Andersen, Vice President for Chr. Hansen's Human Health and Nutrition business unit. “We are pleased that the concept is now also available in the USA, which is clearly one of the most important global markets for probiotics. Jarrow Formulas is a good strategic fit for us as they have a strong reputation for their focus on high quality and efficacious product solutions, and is one of the leading marketers of probiotics in the US.”    

Jarrow Formulas is a formulator and supplier of nutritional supplements including vitamins, minerals, probiotics, standardized herbal concentrates, amino acids, enzymes, and enteral nutrition products. The company was founded in 1976 and today markets its products in the USA, Mexico, Canada, and the world. According to the company, Jarrow promotes optimal health with effective, "cutting edge" formulations that are based on sound scientific research data. Jarrow is actively involved in clinical studies, working with researchers from universities and institutes around the world.

“We are very excited about our partnership with Chr. Hansen and the opportunity to be the first in the US market with a clinically documented oral probiotic concept that addresses women’s health, ” said Jarrow Rogovin, President of Jarrow Formulas. “We're convinced that a lot of women will benefit from this novel probiotic concept. The introduction of Fem-Dophilus will solidify our position as a leading provider of value added probiotics in the US.” 

For more information about the Urex concept and Chr. Hansen's other probiotics and ingredients for human health, contact the company at 800-558-0802 or Innovations@chr-hansen-us.com. For more information on Fem-Dophilus, contact Jarrow Formulas at info@jarrow.com, or 310-204-6936.

Operating from facilities in thirty countries worldwide, Chr. Hansen is a global biotechnology company that provides ingredients to the food, dairy, human health and nutrition, and animal health industries. Based on intensive research, Chr. Hansen works to improve the quality of food and health for people all over the world. The company is a primary supplier of cultures, probiotics, enzymes, colors, flavors, seasonings, sweeteners, and tablet coatings and excipients, which are applied in foods and beverages, pharmaceuticals, dietary supplements, and agricultural products. For more information, visit www.chr-hansen.com.

# # #